George Tidmarsh
Chairman at REVELATION BIOSCIENCES, INC.
Net worth: 3 005 $ as of 2024-04-29
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Jennifer Carver | F | 70 |
Revelation Biosciences Sub, Inc.
Revelation Biosciences Sub, Inc. Medical SpecialtiesHealth Technology Part of Revelation Biosciences, Inc., Revelation Biosciences Sub, Inc. develops medical devices. The company is based in San Diego, CA. James M. Rolke has been the CEO of the company since 2020. Revelation Biosciences Sub was acquired by Petra Acquisition, Inc. on January 11, 2022 for $87.36 million. | 10 years |
Chester Zygmont | M | 44 | 9 years | |
James Rolke | M | 55 |
Revelation Biosciences Sub, Inc.
Revelation Biosciences Sub, Inc. Medical SpecialtiesHealth Technology Part of Revelation Biosciences, Inc., Revelation Biosciences Sub, Inc. develops medical devices. The company is based in San Diego, CA. James M. Rolke has been the CEO of the company since 2020. Revelation Biosciences Sub was acquired by Petra Acquisition, Inc. on January 11, 2022 for $87.36 million. | 4 years |
Craig Johnson | M | 62 | 11 years | |
Sandra Vedrick | F | - | 7 years | |
Lakhmir Chawla | M | 53 | 7 years | |
Curt LaBelle | M | 53 |
Revelation Biosciences Sub, Inc.
Revelation Biosciences Sub, Inc. Medical SpecialtiesHealth Technology Part of Revelation Biosciences, Inc., Revelation Biosciences Sub, Inc. develops medical devices. The company is based in San Diego, CA. James M. Rolke has been the CEO of the company since 2020. Revelation Biosciences Sub was acquired by Petra Acquisition, Inc. on January 11, 2022 for $87.36 million. | 3 years |
Jess Roper | M | 59 |
Revelation Biosciences Sub, Inc.
Revelation Biosciences Sub, Inc. Medical SpecialtiesHealth Technology Part of Revelation Biosciences, Inc., Revelation Biosciences Sub, Inc. develops medical devices. The company is based in San Diego, CA. James M. Rolke has been the CEO of the company since 2020. Revelation Biosciences Sub was acquired by Petra Acquisition, Inc. on January 11, 2022 for $87.36 million. | 4 years |
Michael Snyder | M | - |
Stanford University School of Medicine
| 15 years |
Peter Kim | M | 65 |
Stanford University School of Medicine
Stanford University
| 14 years |
Aaron Davis | M | 45 | 8 years | |
Yvonne Maldonado | M | 68 |
Lucile Packard Foundation for Children’s Health
| - |
Philip Hanno | M | - |
Stanford University School of Medicine
| 8 years |
John W. Day | M | - |
Stanford University School of Medicine
| 13 years |
Vikram Bajaj | M | 46 |
Stanford University School of Medicine
| 10 years |
Walter Greenleaf | M | - |
Stanford University School of Medicine
| 7 years |
Ryan Spitler | M | - |
Stanford University School of Medicine
| 8 years |
Robin Marsden | M | - | - | |
Hannah Valantine | M | 72 |
Stanford University School of Medicine
| 37 years |
Kiki Chang | M | - |
Stanford University School of Medicine
| - |
Megan Alpers | F | - |
Lucile Packard Foundation for Children’s Health
| - |
Siobhan McDonnell | F | - |
Lucile Packard Foundation for Children’s Health
| - |
Greg Muñiz | M | - |
Lucile Packard Foundation for Children’s Health
| - |
Debra Sallen | F | - |
Lucile Packard Foundation for Children’s Health
| - |
Gary Berke | M | - |
Stanford University School of Medicine
| - |
Susan Hoerger | F | - |
Stanford University School of Medicine
| - |
Christi Opitz | F | - |
Stanford University School of Medicine
| - |
Jennifer Rosingana | F | - |
Stanford University School of Medicine
| - |
Mintu Turakhia | M | 50 |
Stanford University School of Medicine
| 16 years |
Mindy Rogers | F | - |
Lucile Packard Foundation for Children’s Health
| - |
J. Crandall | M | 70 |
Lucile Packard Foundation for Children’s Health
| - |
Mark A. Kay | M | 66 |
Stanford University School of Medicine
| 26 years |
Eugene Bauer | M | 81 |
Stanford University School of Medicine
| 36 years |
William J. Maloney | M | - |
Stanford University School of Medicine
| 20 years |
Steven J. Chu | M | 76 |
Stanford University School of Medicine
| 11 years |
John Francis Cogan | M | 76 |
Stanford University
| 44 years |
Paul A. Berg | M | 97 |
Stanford University School of Medicine
| - |
Doug J. MacKenzie | M | 64 |
Lucile Packard Foundation for Children’s Health
| - |
Ken Goldman | M | 73 |
Lucile Packard Foundation for Children’s Health
| - |
Edgar Engleman | M | 78 |
Stanford University School of Medicine
| 34 years |
John Albert Gunn | M | - |
Lucile Packard Foundation for Children’s Health
| - |
Lucy Shapiro | M | 83 |
Stanford University School of Medicine
| 35 years |
Ramon Chavez Márquez | M | 60 |
Stanford University School of Medicine
| 9 years |
Joseph Wu | M | - |
Stanford University School of Medicine
| 11 years |
Alejandro Dorenbaum | M | 64 |
Stanford University School of Medicine
| - |
Manuel Henriquez | M | 60 |
Lucile Packard Foundation for Children’s Health
| - |
Christopher Viehbacher | M | 64 |
Stanford University School of Medicine
| - |
Terrence Blaschke | M | 81 |
Stanford University School of Medicine
| 50 years |
Thomas Raffin | M | 77 |
Stanford University School of Medicine
| - |
Amato Giaccia | M | 65 |
Stanford University School of Medicine
| - |
Roger Kornberg | M | 77 |
Stanford University School of Medicine
| 46 years |
Jillian Manus | F | - |
Stanford University School of Medicine
| 6 years |
K. Christopher Garcia | M | - |
Stanford University School of Medicine
| 25 years |
Thomas C. Südhof | M | 68 |
Stanford University School of Medicine
| - |
Stephen Galli | M | 77 |
Stanford University School of Medicine
| 25 years |
Simon Stertzer | M | 88 |
Stanford University School of Medicine
| 26 years |
James Gillespie | M | - |
Stanford University School of Medicine
| 7 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Jeff Bird | M | 63 |
Stanford University School of Medicine
Horizon Therapeutics, Inc.
Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance.
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA
Horizon Pharma, Inc.
Horizon Pharma, Inc. Pharmaceuticals: MajorHealth Technology Horizon Pharma, Inc. discovers and develops medicines for the treatment of chronic inflammatory diseases. It is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company products include DUEXIS (ibuprofen and famotidine) Tablets, is a proprietary, single-tablet combination of the non-steroidal anti-inflammatory drug ibuprofen and the histamine H2-receptor antagonist famotidine; RAYOS (prednisone) delayed-release tablets, known as LODOTRA outside the U.S., is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. Horizon Pharma was founded on March 23, 2010 and is headquartered in Deerfield, IL.
Stanford University
| 25 years |
Stewart M. Kroll | M | 65 |
Coulter Pharmaceuticals, Inc.
Coulter Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 1995, Coulter Pharmaceutical is engaged in the development of novel drugs and therapies for the treatment of people with cancer and autoimmune diseases. Currently under development is a family of therapeutics based upon two drug discovery platforms: therapeutic antibodies and targeted oncologics.
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | 21 years |
Laura Douglass | F | 59 | 9 years | |
Robert J. de Vaere | M | 66 |
Horizon Therapeutics, Inc.
Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance.
Horizon Pharma, Inc.
Horizon Pharma, Inc. Pharmaceuticals: MajorHealth Technology Horizon Pharma, Inc. discovers and develops medicines for the treatment of chronic inflammatory diseases. It is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company products include DUEXIS (ibuprofen and famotidine) Tablets, is a proprietary, single-tablet combination of the non-steroidal anti-inflammatory drug ibuprofen and the histamine H2-receptor antagonist famotidine; RAYOS (prednisone) delayed-release tablets, known as LODOTRA outside the U.S., is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. Horizon Pharma was founded on March 23, 2010 and is headquartered in Deerfield, IL. | 6 years |
Stephen Wurzburg | M | - |
Stanford University
| 8 years |
Barry L. Golombik | M | - |
Horizon Therapeutics, Inc.
Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance. | - |
Robert H. Rosen | M | 68 | 8 years | |
Tsuneo Yahagi | M | 82 |
Stanford University
| 6 years |
Patrick Enright | M | 62 |
Horizon Therapeutics, Inc.
Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance.
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA
Stanford University
| 9 years |
Gail A. Sloan | F | 61 | 16 years | |
Robert A. Fildes | M | 85 | 21 years | |
Louis C. Bock | M | 59 |
Horizon Therapeutics, Inc.
Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance.
Horizon Pharma, Inc.
Horizon Pharma, Inc. Pharmaceuticals: MajorHealth Technology Horizon Pharma, Inc. discovers and develops medicines for the treatment of chronic inflammatory diseases. It is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company products include DUEXIS (ibuprofen and famotidine) Tablets, is a proprietary, single-tablet combination of the non-steroidal anti-inflammatory drug ibuprofen and the histamine H2-receptor antagonist famotidine; RAYOS (prednisone) delayed-release tablets, known as LODOTRA outside the U.S., is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. Horizon Pharma was founded on March 23, 2010 and is headquartered in Deerfield, IL. | - |
Deirdre Y. Gillespie | M | 67 | 6 years | |
Saiid Zarrabian | M | 71 | - | |
Timothy Walbert | M | 57 |
Horizon Therapeutics, Inc.
Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance.
Horizon Pharma, Inc.
Horizon Pharma, Inc. Pharmaceuticals: MajorHealth Technology Horizon Pharma, Inc. discovers and develops medicines for the treatment of chronic inflammatory diseases. It is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company products include DUEXIS (ibuprofen and famotidine) Tablets, is a proprietary, single-tablet combination of the non-steroidal anti-inflammatory drug ibuprofen and the histamine H2-receptor antagonist famotidine; RAYOS (prednisone) delayed-release tablets, known as LODOTRA outside the U.S., is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. Horizon Pharma was founded on March 23, 2010 and is headquartered in Deerfield, IL. | - |
Dennis Mulroy | M | 69 | 5 years | |
Brett Scott | M | 73 | - | |
Alan W. Marty | M | - |
Stanford University
| 2 years |
M. Robinson | M | - |
Stanford University
| 5 years |
Stephen Fisher | M | 60 |
Stanford University
| 5 years |
Se-Hun Kim | M | 74 |
Stanford University
| 4 years |
Inge Bear | F | - | - | |
Jeffrey Jensen | M | - | - | |
Peter Salovey | M | 66 |
Stanford University
| 4 years |
Katherine Fleming Ashton | F | - |
Stanford University
| 8 years |
Geoff S. Keith | M | - |
Stanford University
| 5 years |
Robert Reay | M | 63 |
Stanford University
| 5 years |
Frank Lexa | M | - |
Stanford University
| 4 years |
Mark D. Matteucci | M | 70 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | - |
Andrew R. Garman | M | 65 |
Stanford University
| 7 years |
Heidi Roizen | F | 66 |
Stanford University
| 7 years |
Chao Chun Lu | M | - |
Stanford University
| 4 years |
David Alan Ward | M | - |
Stanford University
| 8 years |
Andrew Lanza | M | 67 |
Stanford University
| 5 years |
Jeffrey Sherman | M | 69 |
Horizon Pharma, Inc.
Horizon Pharma, Inc. Pharmaceuticals: MajorHealth Technology Horizon Pharma, Inc. discovers and develops medicines for the treatment of chronic inflammatory diseases. It is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company products include DUEXIS (ibuprofen and famotidine) Tablets, is a proprietary, single-tablet combination of the non-steroidal anti-inflammatory drug ibuprofen and the histamine H2-receptor antagonist famotidine; RAYOS (prednisone) delayed-release tablets, known as LODOTRA outside the U.S., is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. Horizon Pharma was founded on March 23, 2010 and is headquartered in Deerfield, IL. | - |
David Schnell | M | 64 |
Stanford University School of Medicine
Stanford University
| 4 years |
Joe Edward Sweeney | M | - |
Stanford University
| 8 years |
Blake Grossman | M | 61 |
Stanford University
| 5 years |
Harold Selick | M | 69 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | 15 years |
Jean-Lou Chameau | M | 71 |
Stanford University
| 4 years |
George Parker | M | 85 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | 13 years |
David Ramsay | M | 59 | 3 years | |
Mark Chao | M | - |
Stanford University School of Medicine
| 7 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- George Tidmarsh
- Personal Network